Activities

Activity Overview

The Pediatric Rheumatology Course 2023features key updates on a wide range of pediatric rheumatology diseases, including juvenile dermatomyositis, JIA, chronic nonbacterial osteomyelitis (CNO), Kawasaki disease, and mental health in children with rheumatic disease. The activity is well-suited for anyone who needs an update in the field of pediatric rheumatology.

The activity consists of recorded sessionsfrom several ACR 2023 live meetings: Pediatric Rheumatology Symposium,Education Exchange, and ACR Convergence. There are six lectures that range induration from 30 minutes to two hours and include a recorded Q&A session.

Target Audience

Primary care providers, rheumatologists, and rheumatology interprofessionals.

Learning Objectives

Upon completion of this activity, participants should be able to:

• Review seminal work on calcinosis development

• Analyze the strengths and limitations of different assessments of calcinosis, including imaging techniques

• Review the evidence to support treatment decisions for calcinosis

• List the multiple ways in which chronic nonbacterial osteomyelitis (CNO) may present in current pediatric rheumatology practice

• Describe the role of whole body MRI in the detection and monitoring of CNO, relative to other imaging modalities

• Describe the medications currently used for CNO and the available evidence supporting their use

• Discuss the management of refractory non-systemic juvenile idiopathic arthritis (JIA) and uveitis

• Discuss withdrawal of DMARDs for well-controlled, non-systemic JIA and uveitis, including timing, strategy, monitoring, and approach to flare

• Review the 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease

• Recognize mental health impact, current care practices, and gaps

• Identify clinical practice change for optimized mental healthcare

• Identify factors contributing to the relationship between rheumatologic disease and mental health in affected youth

• Review recent advances in imaging of Takayasu arteritis (TAK) and how/when to use information from serial imaging to tailor treatments

• Demonstrate which biologics have been studied in TAK and how this can be applied to the pediatric population

• Review advances in vessel wall imaging in childhood primary angiitis of the central nervous system (cPACNS)

• Discuss treatment protocols in cPACNS

Price

• Member: $299

• Nonmember: $499

If you are not a member, consider joining ACR/ARP.

CE & MOC Information

• Credit must be claimed by August 29, 2027, at 11:59 PM ET.

• By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board. 

• After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM and/or ABP diplomates to the ABIM diplomate number and date of birth provided when you claimed credit. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.

• The following credit types must be self-reported to the appropriate board: CME, AAPA, AANC, AWSB ACE, and APA. The certificate is a record of your activity completion.

• All participating healthcare professionals should claim only the credit commensurate with the extent of their participation in this activity. 

Credit Available

• CME: 6.75 AMA PRA Category 1 Credit(s)™

• ABIM MOC: 6.75 Medical Knowledge Points

• ABP MOC: 6.75 Lifelong Learning Points

Designation Statements

Joint Accreditation

In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797

See the ACR's CE Mission Statement. For more information, download the AMA PRA Booklet. 

AMA

The AmericanCollege of Rheumatology designates this enduring material for a maximum of 6.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) and American Board of Pediatrics (ABP)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program and American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM and ABP MOC credit.

Financial Relationship Disclosures

ACR Disclosure Statement

It is the policy of the American College of Rheumatology (ACR) to ensure thatContinuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. 

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

Nature of Financial Relationships

All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:

1. Advisor or review panel member

2. Consultant

3. Employee

4. Officer or Board Member

5. Grant/research support

6. Speaker/honoraria includes speaker’s bureau, symposia, and expert witness

7. Independent contractor

8. Executive role and/or ownership interest

9. Royalties and/or patent beneficiary

10. Intellectual property/patents

11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan

12. Private investigator

13. Expert witness

14. Equity interest

15. Other: specify details 

None: Has no relevant financial relationship(s) with ineligible companies to disclose. 

All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.

Authors

The following authors have no relevant financial relationship(s) with ineligible companies to disclose:

• Hedrich, Christian, MD, PhD - Novartis, 2 (Terminated, August 31, 2021)

• Ferguson, Polly, MD - No financial relationships with ineligible companies to disclose

• Doria, Andrea, MD, PhD, MSc, MBA - Baxalta-Shire, 5 (Ongoing); Novo Nordisk, 5 (Ongoing); Terry Fox Foundation, 5(Ongoing)

• Lood, Christian, PhD - No financial relationships with ineligible companies to disclose

• Schiffenbauer, Adam, MD - AstraZeneca, 5 (Ongoing); Hope Pharmaceuticals, 5 (Ongoing)

• Pilkington, Clarissa, MBBS, BSc,FRCPC, FRCP - No financial relationships with ineligible companies to disclose

• Melissa Mannion, MD - No financial relationships with ineligible companies to disclose

• Joost Swart, MD, PhD - No financial relationships with ineligible companies to disclose

• Ashley M. Cooper, MD - No financial relationships with ineligible companies to disclose

• Mark Gorelik, MD - No financial relationships with ineligible companies to disclose

• Knight, Andrea, MD, MSCE - Pfizer, 6 (Ongoing)

• Vora, Sheetal, MD, MS - No financial relationships with ineligible companies to disclose

• Leever, Alana, PhD - No financial relationships with ineligible companies to disclose

• Edison, Suzanne, MA, MFA - No financial relationships with ineligible companies to disclose

• Susanne (Susa) Benseler, MD, PhD,FRCPC -  No financial relationships with ineligible companies to disclose

• Ozen, Seza, MD, MSc - No financial relationships with ineligible companies to disclose

• Kaitlin Quinn, MD;MHS - No financial relationships with ineligible companies to disclose

Planning Team Members

The following editors and reviewers have no relevant financial relationship(s) with ineligible companies to disclose.

• Adena Batterman, LCSW, MSW

• Belina Yi, D.O.

• Annelle Reed, MSN, CPNP

• Kai Sun, MD, MS

• Dawn Wahezi, MD, MS

• Rebecca Manno, MD, MHS

• Maura Daly Iversen, PT, DPT, SD, MPH,FNAP, FAPTA

• Susan Farrow

• Lawrence Cunningham

• Carlos Ferreira, MA

• Sharon Ross

Editors and Reviewers

The following editors and reviewers have relevant financial relationship(s) with ineligible companies to disclose.

• Kaveh Ardalan, MD, MS – Cabaletta Bio, Inc. 1; Cure JM Foundation5

• Susan Shenoi, MBBS, MS, RhMSUS – Pfizer2; Cabaletta Bio, Inc2; Novartis2; Amgen2

• Lesley Ann Saketkoo, MD, MPH - Argenx1,5; Atyr1,5; Boehringer Ingelheim1,5; Horizon1,5; Janssen1,5; Kadmon1,5; Kinevant1,5; Kyverna1,5; Mallinckrodt1,5; Novartis1,5; UCB1,5

*All of the relevant financial relationships listed for these individuals have been mitigated.

Acknowledgement of Commercial Support

No commercial support was provided for this activity.

Educational Activity Policies

See ACR educational activity policies, including the online enduring activity refund policy.